哌拉西林、阿洛西林、替卡西林、氨曲南和妥布霉素对实验性铜绿假单胞菌肺炎的疗效比较
Comparative efficacies of piperacillin, azlocillin, ticarcillin, aztreonam, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.
作者信息
Schiff J B, Pennington J E
出版信息
Antimicrob Agents Chemother. 1984 Jan;25(1):49-52. doi: 10.1128/AAC.25.1.49.
The therapeutic efficacies of the newer beta-lactam antibiotics piperacillin, azlocillin and aztreonam were compared with the efficacies of ticarcillin and tobramycin in a guinea pig model of experimental Pseudomonas aeruginosa pneumonia. For animals challenged with 2 X 10(8) CFU, tobramycin treatment resulted in survival rates and intrapulmonary killing of pseudomonads which were significantly greater than those found with any of the beta-lactam agents. There were no significant differences noted among the individual beta-lactam agents. When animals were challenged with 200-fold-fewer organisms (10(6) CFU), there was no significant difference between the efficacy of tobramycin and those of the various beta-lactams. These data suggest that tobramycin is particularly valuable in treating more severe P. aeruginosa pneumonia, whereas a number of different beta-lactam agents are of equivalent value in less severe lung infections.
在实验性铜绿假单胞菌肺炎豚鼠模型中，将新型β-内酰胺类抗生素哌拉西林、阿洛西林和氨曲南的治疗效果与替卡西林和妥布霉素的效果进行了比较。对于接种2×10⁸CFU的动物，妥布霉素治疗导致的存活率和肺内假单胞菌杀灭率显著高于任何一种β-内酰胺类药物。各β-内酰胺类药物之间未观察到显著差异。当动物接种的细菌数量减少200倍（10⁶CFU）时，妥布霉素与各种β-内酰胺类药物的疗效之间没有显著差异。这些数据表明，妥布霉素在治疗更严重的铜绿假单胞菌肺炎方面特别有价值，而在不太严重的肺部感染中，多种不同的β-内酰胺类药物具有同等价值。
Zotero 插件